Citations

Mayo Clinic

Showing 10 of 108551 citations.

Complex cutaneous leishmaniasis in a pediatric patient
Dhami, Ramneek K. , Tollefson, Megha M. , Turbeville, Jackson

Pediatric Dermatology | April 15, 2024 | Volume: 41 | Issue: 5 | Pages: 900-903

10.1111/pde.15624 | PMID 38621689 Get It

AbstractCutaneous leishmaniasis (CL), a parasitic infection caused by Leishmania protozoa and transmitted by sandfly bites, can be classified into Old World and New World subtypes. We report a case of a 2‐year‐old female who developed complex CL after travel to Panama. Ultimately, successful treatment required two rounds of liposomal amphotericin B. We report this case for its challenging clinical course and management.
Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways
Knutson, Keith L. , Knutson, Keith L.

The Journal of Immunology | April 15, 2024 | Volume: 212 | Issue: 9 | Pages: 1397-1405

10.4049/jimmunol.2300674 | PMID 38621195 Get It

Abstract The advent of immune checkpoint blockade therapy has revolutionized cancer treatments and is partly responsible for the significant decline in cancer-related mortality observed during the last decade. Immune checkpoint inhibitors, such as anti–programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1), have demonstrated remarkable clinical successes in a subset of cancer patients. However, a considerable proportion of patients remain refractory to immune checkpoint blockade, prompting the exploration of mechanisms of treatment resistance. Whereas much emphasis has been placed on the role of PD-L1 and PD-1 in regulating the activity of tumor-infiltrating T cells, recent studies have now shown that this immunoregulatory axis also directly regulates myeloid cell activity in the tumor microenvironment including tumor-infiltrating dendritic cells. In this review, I discuss the most recent advances in the understanding of how PD-1, PD-L1, and programmed cell death ligand 2 regulate the function of tumor-infiltrating dendritic cells, emphasizing the need for further mechanistic studies that could facilitate the development of novel combination immunotherapies for improved cancer patient benefit.
Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma
Klatte, Derk C.F. , Starr, Jason S. , Clift, Kristin , Hardway, Heather D , Hooft, Jeanin E. van , Leerdam, Monique E. van , Potjer, Thomas P. , Presutti, R. John , Riegert‐Johnson, Douglas L. , Wallace, Michael B. , Bi, Yan , Clift, Kristin E , van Hooft, Jeanin E , van Leerdam, Monique E , Presutti, Richard J , Wallace, Michael B , Klatte, D C F , Hardway, Heather

JCO Oncology Practice | April 15, 2024 | Volume: 20 | Issue: 8 | Pages: 1081-1090

10.1200/op.23.00447 | PMID 38621197 Get It

PURPOSE Guidelines recommend germline genetic testing (GT) for patients with pancreatic ductal adenocarcinoma (PDAC). This study aims to evaluate the utilization and outcomes of multigene panel GT in patients with PDAC. METHODS This retrospective, multisite study included patients with PDAC diagnosed between May 2018 and August 2020 at Mayo Clinic Arizona, Florida, and Minnesota. Discussion, uptake, and outcomes of GT were compared before (May 1, 2018-May 1, 2019) and after (August 1, 2019-August 1, 2020) the guideline update, accounting for a transition period. RESULTS The study identified 533 patients with PDAC, with 321 (60.2%) preguideline and 212 (39.8%) postguideline. Patient characteristics did not differ between the preguideline and postguideline periods. GT was discussed in 34.3% (110 of 321) of preguideline and 39.6% (84 of 212) of postguideline patients (odds ratio [OR], 1.26 [95% CI, 0.88 to 1.80]) and subsequently performed in 80.9% (89 of 110) of preguideline and 75.0% (63 of 84) of postguideline patients (OR, 1.10 [95% CI, 0.75 to 1.61]). Of 152 tested patients, 26 (17.1%) had a pathogenic variant (PV), of whom 17 (11.2%; 17 of 152) were PDAC-associated. Over the entire study period, GT was more likely in younger patients (65 v 70 years; P < .001), those seen by a medical oncologist (82.9% v 69.0%; P < .001), and those surviving more than 12 months from diagnosis (70.4% v 43.4%; P < .001). Demographics and personal/family cancer history were comparable between patients with and without a PDAC PV. CONCLUSION GT remains underutilized despite National Comprehensive Cancer Network guideline recommendations. Given the poor prognosis of PDAC and potential implications of GT, efforts to increase utilization are needed to provide surveillance and support to both patients with PDAC and at-risk family members.
How I Made My Classical Hematology Practice More Efficient
Padrnos, Leslie , Shah, Surbhi

The Hematologist | April 15, 2024 | Volume: 21 | Issue: 3 | Pages: No page available

10.1182/hem.v21.3.202433 Get It

Comparison of Contralateral vs Ipsilateral Vein Graft for Traumatic Vascular Injury Repair: A Cohort From PROOVIT
Siddiqi, Noreen, Hu, Parker , Stonko, David P. , DuBose, Joseph J. , Hurst, Stuart , Betzold, Richard , Morrison, Jonathan, Stonko, David P , Lammers, Daniel T. , Hashmi, Zain G. , Morrison, Jonathan J.

The American Surgeon™ | April 15, 2024 | Volume: 90 | Issue: 9 | Pages: 2310-2313

10.1177/00031348241246167 | PMID 38621410 Get It

Traumatic injury leading to arterial damage has traditionally been repaired using autologous vein graft from the contralateral limb. This often requires a secondary surgical site and the potential of prolonged operative time for patients. We sought to assess the use of ipsilateral vs contralateral vein grafts in patients who experienced traumatic extremity vascular injury. A multicenter database was queried to identify arterial injuries requiring operative intervention with vein grafting. The primary outcome of interest was need for operative reintervention. Secondary outcomes included risk of thrombosis, infection, and intensive care unit length of stay. 358 patients (320 contralateral and 38 ipsilateral) were included in the analysis. The ipsilateral vein cohort did not display a statistically significant decrease in need for reoperation when compared to the contralateral group (11% vs 23%; OR 0.41, 95% CI −0.07-1.3; P = .14). Contralateral repair was associated with longer median intensive care unit (ICU) LOS (4.3 vs 3.1 days; P < .01).
eCLIPs bifurcation remodeling system for treatment of wide-neck bifurcation aneurysms: A systematic review and meta-analysis of safety and efficacy
Ghozy, Sherief , Ramzan, Abdullah , Motawei, Ahmed Sallam, Abdelghaffar, Mariam , Dmytriw, Adam A. , Kallmes, David F. , Kadirvel, Ramanathan , Dmytriw, Adam A , Ghozy, Sherief , Kobeissi, Hassan

The Neuroradiology Journal | April 15, 2024 | Volume: 37 | Issue: 6 | Pages: 699-704

10.1177/19714009241247463 | PMID 38621366 Get It

Background Wide neck bifurcation aneurysms (WNBAs) are a subtype of aneurysms that are especially complex to treat. We aim to conduct a systematic review and meta-analysis to synthesize the available literature on the safety and efficacy of employing endovascular clip system (eCLIPs) in the treatment of WNBAs. Methods We report this study in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines. PubMed, Embase, Web of Science, and Scopus were queried for this review. Screening and extraction were performed by at least two authors to ensure accuracy and completeness, and a senior author arbitrated any discrepancies. All data were analyzed using R software version 4.3.0. and random-effects model. Results Four studies were finally included, of which three were prospective and one was retrospective. Successful adjunctive coiling occurred in 91.38% (95% CI = 70.71–97.9) of cases and overall technical success was achieved in 88.61% (95 CI = 75.54–95.15) of cases. The pooled complete occlusion (Raymond-Roy Class I) was 50.65% (95% CI = 39.63–61.60) and adequate occlusion (Raymond-Roy Class I/II) was 84.42% (95% CI = 74.53–90.93). Thrombo-embolic complication had a pooled rate of 1.22% (95% CI = 0.17–8.15), retreatment rate was 6.10% (95% CI = 2.56–13.83), and mortality reported in 3.66% (95% CI = 1.18–10.74) of patients. Conclusion The use of eCLIPs may be a safe and efficacious treatment for WNBAs. Future randomized controlled trials are needed for further validation of the findings.
Pro-Con Debate: Universal Versus Selective Continuous Monitoring of Postoperative Patients
Blike, George T. , McGrath, Susan P. , Kinney, Michelle A. O. , Gali, Bhargavi , Ochs Kinney, Michelle A

Anesthesia & Analgesia | April 15, 2024 | Volume: 138 | Issue: 5 | Pages: 955-966

10.1213/ane.0000000000006840 | PMID 38621283 Get It

In this Pro-Con commentary article, we discuss use of continuous physiologic monitoring for clinical deterioration, specifically respiratory depression in the postoperative population. The Pro position advocates for 24/7 continuous surveillance monitoring of all patients starting in the postanesthesia care unit until discharge from the hospital. The strongest arguments for universal monitoring relate to inadequate assessment and algorithms for patient risk. We argue that the need for hospitalization in and of itself is a sufficient predictor of an individual’s risk for unexpected respiratory deterioration. In addition, general care units carry the added risk that even the most severe respiratory events will not be recognized in a timely fashion, largely due to higher patient to nurse staffing ratios and limited intermittent vital signs assessments (e.g., every 4 hours). Continuous monitoring configured properly using a “surveillance model” can adequately detect patients' respiratory deterioration while minimizing alarm fatigue and the costs of the surveillance systems. The Con position advocates for a mixed approach of time-limited continuous pulse oximetry monitoring for all patients receiving opioids, with additional remote pulse oximetry monitoring for patients identified as having a high risk of respiratory depression. Alarm fatigue, clinical resource limitations, and cost are the strongest arguments for selective monitoring, which is a more targeted approach. The proponents of the con position acknowledge that postoperative respiratory monitoring is certainly indicated for all patients, but not all patients need the same level of monitoring. The analysis and discussion of each point of view describes who, when, where, and how continuous monitoring should be implemented. Consideration of various system-level factors are addressed, including clinical resource availability, alarm design, system costs, patient and staff acceptance, risk-assessment algorithms, and respiratory event detection. Literature is reviewed, findings are described, and recommendations for design of monitoring systems and implementation of monitoring are described for the pro and con positions.
Concordance of Blood Glucose and CGM During a Pilot Trial of Automated Insulin Delivery in Type 1 Diabetes Pregnancies
Kaur, Ravinder Jeet , Castorino, Kristin , Wood‐Wentz, Christina M. , Rizvi, Shafaq R., Özaslan, Başak , O’Malley, Grenye , Trinidad, Mari Charisse, Levister, Camilla, Church, Mei Mei , Desjardins, Donna, Ogyaadu, Selassie, Reid, Corey, Bailey, Kent R. , Pinsker, Jordan E. , Dassau, Eyal , Kudva, Yogish C. , Wood-Wentz, Christina M, Kudva, Yogish C. , Levy, Carol J. , Rizvi, Shafaq, Doyle, Francis J.

Journal of the Endocrine Society | April 15, 2024 | Volume: 8 | Issue: 6 | Pages: No page available

10.1210/jendso/bvae071 | PMID 38721109 Get It

Abstract Background Customized and standard automated insulin delivery (AID) systems for use in pregnancies of women with preexisting type 1 diabetes (T1D) are being developed and tested to achieve pregnancy appropriate continuous glucose monitoring (CGM) targets. Guidance on the use of CGM for treatment decisions during pregnancy in the United States is limited. Methods Ten pregnant women with preexisting T1D participated in a trial evaluating at-home use of a pregnancy-specific AID system. Seven-point self-monitoring of blood glucose (SMBG) was compared to the closest sensor glucose (Dexcom G6 CGM) value biweekly to assess safety and reliability based on the 20%/20 mg/dL criteria. Results All participants completed the study with 7 participants satisfying the safety and reliability criteria with a mean absolute relative difference of 10.3%. Three participants did not fulfill the criteria, mainly because the frequency of SMBG did not meet the requirements. Conclusion Dexcom G6 CGM is safe and accurate in the real-world setting for use in pregnant women with preexisting T1D with reduced SMBG testing as part of a pregnancy-specific AID system.
Point-CounterpointBispecific Antibodies in Earlier Lines of Therapy for Patients With Multiple Myeloma: A Bright Future for the New Kids on the Block
Lin, Yi

The Hematologist | April 15, 2024 | Volume: 21 | Issue: 3 | Pages: No page available

10.1182/hem.v21.3.202431 Get It

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2
Bryce, Alan H. , Crawford, E. David , Beltran, Himisha , Petrylak, Daniel P. , Armstrong, Andrew J. , Boike, Thomas , Calais, Jérémie , Chapin, Brian F. , Cookson, Michael S. , Davis, John W. , Dorff, Tanya B. , Eggener, Scott E. , Feng, Felix Y. , Higano, Celestia S. , Poage, Wendy, Scher, Howard I. , Sieber, Paul , Srinivas, Sandy, Zhang, Tian , Koo, Phillip J. , Beltran, Himisha , Cooperberg, Matthew R , Antonarakis, Emmanuel S , Aparicio, Ana M , Calais, Jeremie , Morris, Michael J , Scher, Howard I , Bryce, Alan H , Armstrong, Andrew J , Agarwal, Neeraj , Hussain, Maha , Shore, Neal D. , Spratt, Daniel E. , Tagawa, Scott T. , Carducci, Michael A. , Gleave, Martin , Iagaru, Andrei H. , Morgans, Alicia K. , Morris, Michael J. , Murray, Katie S. , Rettig, Matthew B. , Sartor, Oliver , Small, Eric J. , Yu, Evan Y

JU Open Plus | April 15, 2024 | Volume: 2 | Issue: 4 | Pages: No page available

10.1097/ju9.0000000000000138 | PMID 38774467 Get It

Background: Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are encountering increasingly challenging clinical scenarios, with limited guidance from the current literature. Materials and Methods: The US Prostate Cancer Conference (USPCC) is a multidisciplinary meeting of prostate cancer experts intended to address the many challenges of prostate cancer management. At the first annual USPCC meeting, areas of controversy and consensus were identified during a 2-day meeting that included expert presentations, full-panel discussions, and postdiscussion responses to questions developed by the USPCC cochairs and session moderators. Results: This narrative review covers the USPCC expert discussion and perspectives relevant to mCRPC, including neuroendocrine/aggressive-variant prostate cancer (NEPC/AVPC). Areas of broad agreement identified among USPCC experts include the benefits of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with BRCA1/2 mutations, the use of radioligand therapy in patients with prostate-specific membrane antigen (PSMA)–positive mCRPC, and the need for clinical trials that address real-world clinical questions, including the performance of novel therapies when compared with modern standard-of-care treatment. Ongoing areas of controversy and uncertainty included the appropriateness of PARP inhibitors in patients with non-BRCA1/2 mutations, the optimal definition of PSMA positivity, and systemic therapies for patients with NEPC/AVPC after progression on platinum-based therapies. Conclusions: The first annual USPCC meeting identified several areas of controversy in the management of mCRPC, highlighting the urgent need for clinical trials designed to facilitate treatment selection and sequencing in this heterogeneous disease state.